BEAM | Cancer information - Cancer Research UK
BEAM is the name of a combination of chemotherapy drugs. You usually have it before you have a stem cell transplant for Hodgkin or non-Hodgkin lymphoma. Find out about how you have it, possible side effects and other important information.
BEAM for Stem Cell Transplant - ChemoExperts
BEAM (Carmustine + Etoposide + Cytarabine + Melphalan) is a Chemotherapy Regimen for Autologous Stem Cell Transplant (autoSCT) How does BEAM work? Each of the medications in BEAM are designed to slow the growth of and kill cancer cells.
BEAM Chemotherapy: Combination Chemotherapy Regimens - Lymphoma Info
BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the context of Hodgkin's lymphoma that includes dexa-BEAM and mini-BEAM. They are also used as salvage or preparative regimens, some prior to stem cell transplantations.
BEAM or BeEAM High-Dose Chemotherapy Followed By ASCT: …
2016年12月2日 · The BEAM (carmustine (BCNU), etoposide, aracytin and melphalan) standard conditioning regimen in autologous stem-cell transplantation is widely used since 1990 in patients with relapsed/refractory non Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) who remain sensitive to salvage therapy.
BEAM and mini-BEAM - Macmillan Cancer Support
BEAM and mini-BEAM are chemotherapy treatments. It is best to read this information about BEAM and mini-BEAM with our general information about chemotherapy and the type of cancer you have. BEAM is a combination of 4 treatments: B – carmustine (BiCNU®) E – etoposide; A – cytarabine (Ara-C®) M – melphalan.
405-Autologous conditioning BEAM (carmustine etoposide ... - eviQ
It commonly develops following anti-cancer treatment, radiation therapy to the head, neck or oesophagus, and high-dose chemotherapy followed by a blood and marrow transplant (BMT). Read more about oral mucositis and stomatitis
Outpatient BEAM Using Daily Etoposide and Cytarabine with …
2019年11月13日 · High dose therapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) followed by autologous hematopoietic stem cell transplantation (AHCT) is the most common consolidation therapy for chemosensitive patients with relapsed/refractory Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) in the US.
Mini BEAM with Full-Dose of Melphalan (beaM) As a …
2016年12月2日 · We used a modified mini-BEAM as conditioning regimen with full dose of melphalan (140mg/m 2). This dose was also used due to its efficacy as conditioning regimen in patients with multiple myeloma undergoing ASCT who are elderly or have kidney impairment.
Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide ...
2024年8月13日 · Autologous stem cell transplantation (ASCT) is a pivotal treatment for lymphoma patients. The BeEAM regimen (Bendamustine, Etoposide, Cytarabine, Melphalan) traditionally relies on cryopreservation, whereas the CEM regimen (Carboplatin, Etoposide, Melphalan) has been optimized for short-duration administration without the need for cryopreservation.
Autologous HSCT | HemOnc.org - A Hematology Oncology Wiki
Unlike the other chemotherapy regimen pages, this one is not disease-specific. Rather, this is a gathering point for all autologous hematopoietic stem cell transplant (HSCT) conditioning regimens. Unless otherwise specified, the day before HSCT is day -1, the day of HSCT is day 0, and the day after HSCT is day +1.